skip to content
Primary navigation

Entresto

Drug - Entresto™ (sacubitril/valsartan tablets) [Novartis.]

May 2016

Therapeutic area - Heart failure

Approval criteria

  • Patient has a diagnosis of chronic heart failure with NYHA functional class of II-IV AND
  • Has a left ventricular ejection fraction ≤ 40% AND
  • Patient will be using sacubitril/valsartan in combination with a beta-blocker or has a contraindication to a beta-blocker AND
  • Patient has tried and failed (or has a contraindication to) an ACE inhibitor or ARB, and therapy was at a therapeutic dosage AND
  • If patient is currently taking an ACE inhibitor or ARB, the ACE inhibitor or ARB therapy will be discontinued 

Quantity limit

Maximum of 2 tablets per day (68 tablets per 34 days)

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top